Article summary
This randomised, outcome-assessor-blinded pilot trial (n=30) assessed intravenous ketamine, psychotherapy, or their combination for adults with moderate-to-severe chronic neuropathic pain. Combining ketamine with psychotherapy was feasible and acceptably safe, with clinically meaningful reductions in pain interference and intensity observed across groups, although adherence targets were only partly met.
Continue to the original publication for the complete article.